NASDAQ:FIXX - Homology Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.50 +0.48 (+2.40 %)
(As of 11/18/2018 04:00 PM ET)
Previous Close$20.50
Today's Range$19.71 - $21.0650
52-Week Range$15.07 - $24.40
Volume740,504 shs
Average Volume103,623 shs
Market Capitalization$768.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FIXX
Previous Symbol
CUSIPN/A
Phone781-301-7277

Debt

Debt-to-Equity RatioN/A
Current Ratio13.24
Quick Ratio24.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.67 per share
Price / Book3.62

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-29,990,000.00
Net MarginsN/A
Return on Equity-57.20%
Return on Assets-24.90%

Miscellaneous

Employees67
Outstanding Shares37,500,000
Market Cap$768.67 million
OptionableNot Optionable

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

How were Homology Medicines' earnings last quarter?

Homology Medicines Inc (NASDAQ:FIXX) released its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.37) by $0.03. The firm earned $0.95 million during the quarter. View Homology Medicines' Earnings History.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Homology Medicines.

What price target have analysts set for FIXX?

5 equities research analysts have issued 1 year target prices for Homology Medicines' shares. Their forecasts range from $18.50 to $35.00. On average, they expect Homology Medicines' stock price to reach $27.6250 in the next year. This suggests a possible upside of 34.8% from the stock's current price. View Analyst Price Targets for Homology Medicines.

What is the consensus analysts' recommendation for Homology Medicines?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Homology Medicines.

Has Homology Medicines been receiving favorable news coverage?

Press coverage about FIXX stock has trended neutral on Sunday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Homology Medicines earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Homology Medicines' key competitors?

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the folowing people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 55)
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 62)
  • Mr. Albert Seymour Ph.D., Chief Scientific Officer (Age 50)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Dr. Siyamak Rasty Ph.D., Chief Operating Officer (Age 54)

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

When did the company's lock-up period expire?

Homology Medicines' lock-up period expired on Monday, September 24th. Homology Medicines had issued 9,000,000 shares in its public offering on March 28th. The total size of the offering was $144,000,000 based on an initial share price of $16.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (6.28%), JPMorgan Chase & Co. (6.01%), JPMorgan Chase & Co. (6.01%), Vivo Capital LLC (3.10%), BlackRock Inc. (1.66%) and Franklin Resources Inc. (1.05%). Company insiders that own Homology Medicines stock include James E Flynn and Vida Ventures, Llc. View Institutional Ownership Trends for Homology Medicines.

Which major investors are selling Homology Medicines stock?

FIXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Vivo Capital LLC and Victory Capital Management Inc.. View Insider Buying and Selling for Homology Medicines.

Which major investors are buying Homology Medicines stock?

FIXX stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Global Thematic Partners LLC, Sphera Funds Management LTD., BlackRock Inc., Franklin Resources Inc., Rhumbline Advisers and Wells Fargo & Company MN. Company insiders that have bought Homology Medicines stock in the last two years include James E Flynn and Vida Ventures, Llc. View Insider Buying and Selling for Homology Medicines.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $20.50.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $768.67 million. Homology Medicines employs 67 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is http://www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is One Patriots Park, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.


MarketBeat Community Rating for Homology Medicines (NASDAQ FIXX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  31 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Homology Medicines and other stocks. Vote "Outperform" if you believe FIXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FIXX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel